Moleculin Biotech, Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Moleculin reported positive interim Phase 2/3 MIRACLE trial data showing complete remission (CR) rates of 43% and 36% in two Annamycin arms versus 12% control in relapsed/refractory AML (n=45). The company raised $9.3M in post-quarter financing and expects cash to fund operations into Q1 2027. Part A enrollment (90 patients) targeted for September 2026 completion with data readout December 2026–February 2027; Part B initiation expected H1 2027.
Why this rating
Positive clinical efficacy data and $9.3M financing (105% of market cap) extend runway materially; maintains lead program momentum but capital needs remain acute long-term.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.